Recombinant Timothy grass pollen allergoids - Allergopharma

Drug Profile

Recombinant Timothy grass pollen allergoids - Allergopharma

Alternative Names: High-dose rPhleum; rPhleum

Latest Information Update: 02 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomay
  • Developer Allergopharma
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Grass pollen hypersensitivity; Seasonal allergic rhinitis

Most Recent Events

  • 02 Dec 2015 Phase III development is ongoing in the EU
  • 28 Jan 2014 Allergopharma completes a phase III trial in Seasonal allergic rhinitis (in adolescents, in adults) in Germany and Poland (EudraCT2009-011504-36)
  • 01 Mar 2013 Allergopharma completes its AMETHYST trial for Seasonal allergic rhinitis (in adults) in Germany and Italy (NCT00671268)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top